EXCIVION LTD has a total of 15 patent applications. It decreased the IP activity by 72.0%. Its first patent ever was published in 2017. It filed its patents most often in EPO (European Patent Office), Australia and Brazil. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are CHINA INST VETERINARY DRUGS CONTROL, BIOCLONES PTY LTD and MACFARLANE BURNET INST FOR MEDICAL RES & PUBLIC HEALTH LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 2 | |
#2 | Australia | 1 | |
#3 | Brazil | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | United Kingdom | 1 | |
#7 | Hungary | 1 | |
#8 | Israel | 1 | |
#9 | Republic of Korea | 1 | |
#10 | Mexico | 1 | |
#11 | Peru | 1 | |
#12 | Philippines | 1 | |
#13 | Singapore | 1 | |
#14 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Therapeutic chemical compounds | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Laing Peter | 11 |
#2 | Peter Laing | 2 |
Publication | Filing date | Title |
---|---|---|
GB202017282D0 | Adjuvant composition | |
CA3025076A1 | Variant flavivirus envelope sequences and uses thereof |